p.101 抽出テキスト

1222. Tu SJ, Gallagher C, Elliott AD, Linz D, Pitman BM, Hendriks JML, et al. Risk thresholds for total and beverage-specific alcohol consumption and incident atrial fibrillation. JACC Clin Electrophysiol 2021;7:1561–9. https://doi.org/10.1016/j.jacep.2021.05.013 1223. Lee JW, Roh SY, Yoon WS, Kim J, Jo E, Bae DH, et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. Eur J Prev Cardiol 2024;31:49–58. https://doi.org/10.1093/eurjpc/zwad270 1224. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13: 123. https://doi.org/10.1186/s12933-014-0123-x 1225. Tseng CH. Metformin use is associated with a lower incidence of hospitalization for atrial fibrillation in patients with type 2 diabetes mellitus. Front Med (Lausanne) 2021; 7:592901. https://doi.org/10.3389/fmed.2020.592901 1226. Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol 2020;19:130. https://doi.org/10.1186/s12933-020-01105-5 1227. Srivatsa UN, Malhotra P, Zhang XJ, Beri N, Xing G, Brunson A, et al. Bariatric surgery to aLleviate OCcurrence of atrial fibrillation hospitalization—BLOC-AF. Heart Rhythm O2 2020;1:96–102. https://doi.org/10.1016/j.hroo.2020.04.004 1228. Hoskuldsdottir G, Sattar N, Miftaraj M, Naslund I, Ottosson J, Franzen S, et al. Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study. J Am Heart Assoc 2021;10:e019323. https://doi.org/10.1161/JAHA.120.019323 1229. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Sharma K, Watthanasuntorn K, Lertjitbanjong P, et al. Incident atrial fibrillation in patients undergoing bariatric surgery: a systematic review and meta-analysis. Intern Med J 2020;50:810–7. https:// doi.org/10.1111/imj.14436 1230. Lynch KT, Mehaffey JH, Hawkins RB, Hassinger TE, Hallowell PT, Kirby JL. Bariatric surgery reduces incidence of atrial fibrillation: a propensity score-matched analysis. Surg Obes Relat Dis 2019;15:279–85. https://doi.org/10.1016/j.soard.2018.11.021 1231. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 2016;68:2497–504. https://doi.org/10.1016/j.jacc.2016.09.940 1232. Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlöf B, et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension 2015;66:368–73. https://doi.org/10.1161/ HYPERTENSIONAHA.115.05728 1233. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712–9. https://doi.org/10.1016/j.jacc.2004.10. 068 1234. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403–11. https://doi.org/10.1097/HJH.0b013e 3282f35c67 1235. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010;152:78–84. https://doi.org/10.7326/0003-4819-152-2- 201001190-00005 1236. Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, et al. Pharmacologic prevention of incident atrial fibrillation: long-term results from the ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). Circ Arrhythm Electrophysiol 2017;10:e005463. https://doi.org/10.1161/ CIRCEP.117.005463 1237. Butt JH, Docherty KF, Jhund PS, de Boer RA, Böhm M, Desai AS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail 2022;24:513–25. https://doi.org/10.1002/ejhf.2381 1238. Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE 2022;17:e0263131. https://doi.org/10.1371/journal.pone.0263131 1239. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep 2013;15:330. https://doi.org/10.1007/s11886-012- 0330-6 1240. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study). Am J Cardiol 2014;114:1217–22. https://doi.org/10.1016/j.amjcard.2014.07.045 1241. Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol 2020;19:198. https://doi.org/10.1186/s12933-020-01176-4 1242. Chang CY, Yeh YH, Chan YH, Liu JR, Chang SH, Lee HF, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol 2017;16:159. https://doi.org/10. 1186/s12933-017-0640-5 1243. Ostropolets A, Elias PA, Reyes MV, Wan EY, Pajvani UB, Hripcsak G, et al. Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol 2021; 14:e009115. https://doi.org/10.1161/CIRCEP.120.009115 1244. Proietti R, Lip GYH. Sodium-glucose cotransporter 2 inhibitors: an additional management option for patients with atrial fibrillation? Diabetes Obes Metab 2022;24: 1897–900. https://doi.org/10.1111/dom.14818 1245. Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A new hope: sodiumglucose cotransporter-2 inhibition to prevent atrial fibrillation. J Cardiovasc Dev Dis 2022;9:236. https://doi.org/10.3390/jcdd9080236 1246. Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther 2023;37: 561–9. https://doi.org/10.1007/s10557-022-07319-x 1247. Elliott AD, Maatman B, Emery MS, Sanders P. The role of exercise in atrial fibrillation prevention and promotion: finding optimal ranges for health. Heart Rhythm 2017;14: 1713–20. https://doi.org/10.1016/j.hrthm.2017.07.001 1248. Newman W, Parry-Williams G, Wiles J, Edwards J, Hulbert S, Kipourou K, et al. Risk of atrial fibrillation in athletes: a systematic review and meta-analysis. Br J Sports Med 2021;55:1233–8. https://doi.org/10.1136/bjsports-2021-103994 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026